Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL 

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma. 

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

OncLive App

Interactive Tools

Biomarker Consortium

Subscribe

 team as an assistant editor in 2025 after previously working on the 

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Health Canada has approved a quizartinib-based regimen for the treatment of patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Health Canada Approves Quizartinib Plus Chemotherapy for Newly Diagnosed FLT3-ITD+ AML

Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Jonathan Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET–overexpressing, nonsquamous, EGFR wild-type advanced NSCLC.

LUMINOSITY Data Continue to Highlight Utility of Telisotuzumab Vedotin in c-MET–Overexpressing NSCLC

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.

Ibrutinib Plus Venetoclax and A CD20 Monoclonal Antibody Increases MRD Negativity in Untreated MCL

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

December 2009

Latest Conference Coverage